Literature DB >> 2296199

Cystadenocarcinoma of the pancreas: neo-adjuvant therapy and CEA monitoring.

D Wood1, A W Silberman, L Heifetz, L Memsic, M M Shabot.   

Abstract

Cystadenocarcinoma of the pancreas is generally considered to be unresponsive to chemotherapy and radiation therapy. We present two cases of laparotomy-proven unresectable cystadenocarcinoma which responded to intravenous 5-fluorouracil (1,000 mg/m2/24 hr x 5 days x 2) and 4,000 rads of radiation therapy. Both patients had objective response with marked shrinkage of the tumor as determined by clinical examination and computed tomography. At reexploration both tumors had become completely resectable with histologically clear margins and negative lymph nodes. Carcinoembryonic antigen (CEA) levels were elevated in both patients at initial presentation (86 and 71 ng/ml). The CEA levels declined to 19.9 and 66.0 ng/ml, respectively, after neo-adjuvant therapy, and both fell to normal levels after resection. Although surgical resection has been considered the only curative therapy for patients with pancreatic cystadenocarcinoma, we suggest that preoperative irradiation and chemotherapy may reduce the size of seemingly unresectable tumors. We also recommend serial CEA determinations in patients with levels initially elevated as a marker of the response to neo-adjuvant and operative therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2296199     DOI: 10.1002/jso.2930430115

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

Review 1.  Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions.

Authors:  Michael G Sarr; Michel Murr; Thomas C Smyrk; Charles J Yeo; Carlos Fernandez-del-Castillo; Robert H Hawes; Patrick C Freeny
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

2.  Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association.

Authors:  J Le Borgne; L de Calan; C Partensky
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

Review 3.  Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

Authors:  Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

4.  Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms?

Authors:  M G Sarr; H A Carpenter; L P Prabhakar; T F Orchard; S Hughes; J A van Heerden; E P DiMagno
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

5.  Mucinous cystadenocarcinoma of the pancreas - outcome following different modes of treatment.

Authors:  Josefin Björk Werner; Christian Sturesson; Sigmund Dawiskiba; Roland Andersson
Journal:  Ann Gastroenterol       Date:  2011

6.  Metastatic adenocarcinoma of the pancreas presents as metastases to the axillary/supraclavicular region as the first sign of the disease.

Authors:  Blake A Stewart; Abdul Adjei; Xiaohong Zhang; Jacqueline C Oxenberg
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2017-11-30

7.  Targetable IDH1 mutation identified in a rare case of pancreatic serous cystadenocarcinoma but not a series of serous cystadenomas.

Authors:  Yuxi Zhang; Autumn Hammonds; Karen Tran-Harding; Kurt B Schaberg; Rashmi T Nair; Chi Wang; Yuanyuan Wu; Prakash K Pandalai; Jill Kolesar; Joseph Kim; Michael J Cavnar
Journal:  J Surg Case Rep       Date:  2022-03-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.